Low-dose psilocybin, a naturally occurring psychedelic compound, may be a promising therapy for mood issues including depression and anxiety in people with Parkinson’s disease, according to data from a pilot Phase 2 clinical trial. In addition to significant reductions in depression and anxiety, results from the trial (NCT04932434)…
Blocking the inflammatory protein ASC with IC 100, ZyVersa Therapeutics’ experimental therapy to reduce inflammation, prevented the activation of the inflammasome in microglia — the brain’s resident immune cells — and the start and perpetuation of an inflammatory response. That’s according to results from a study announced by the…
The STING protein, which has been linked to cell damage and brain inflammation — two known contributing factors to Parkinson’s disease and other neurodegenerative diseases — has a dual function, a study found. The researchers said their finding could have implications for treating Parkinson’s and other neurodegenerative diseases. Lysosomes,…
A new artificial intelligence (AI) tool may help predict the structure of amyloid fibrils, that is, misfolded protein fibers that accumulate in the brain of people with neurodegenerative diseases such as Parkinson’s. Called Ribbonfold, the tool is designed to address the complex and variable structures of misfolded proteins by…
Treatment for up to three years with Onapgo (apomorphine hydrochloride) — approved in the U.S. earlier this year as an add-on therapy for advanced Parkinson’s disease — significantly and sustainably reduced off time, when symptoms are not fully controlled, in adults with the neurodegenerative condition. Importantly, the researchers…
Although physical exercise has well-established benefits for people with Parkinson’s disease, too much of it may worsen fatigue and motor symptoms, according to a report of two cases in the U.K. Both patients believed that intense exercise could help them overcome the disease, including reversing the degeneration of dopaminergic…
Vyalev (foscarbidopa and foslevodopa) demonstrated a favorable long-term safety and tolerability profile, along with sustained motor symptom control, in Parkinson’s disease patients who participated in the extension part of a Phase 3 trial (NCT03781167). Results from nearly two years of the extension study (NCT04379050) showed…
Nitrase Therapeutics’ NDC-0524, an antibody therapy for Parkinson’s disease, significantly reduced alpha-synuclein aggregation and spreading in mouse models of the disease, according to preclinical data released by the company. The antibody targets nitrated alpha-synuclein, a misfolded form of the protein that forms toxic clumps in dopaminergic neurons, the nerve cells…
A new collaborative effort between Mayo Clinical Laboratories and Amprion will expand access to the diagnostic company’s SAAmplify–αSYN test — designed to detect the presence of abnormal alpha-synuclein protein in people suspected of having neurodegenerative diseases — across the U.S., according to a joint press release.
Researchers at the University of Delaware have developed a model that combines artificial intelligence with magnetic resonance elastography (MRE) to measure brain stiffness and volume for predicting brain age. MRE is a noninvasive method that can measure changes in brain stiffness by using a gentle vibration of a person’s head…
Get regular updates to your inbox.
